
Meridian Bioscience VIVO
Quarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Operating Income 2011-2026 | VIVO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.4 M | 93 M | 61.3 M | 32.7 M | 31.6 M | 37.4 M | 51.4 M | 56.1 M | 52.4 M | 57.3 M | 49.3 M | 40 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 93 M | 31.6 M | 51.4 M |
Quarterly Operating Income Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.1 M | - | - | 36.1 M | 20.3 M | - | 15.7 M | 34.2 M | 34.7 M | 51.8 M | 34.7 M | 34.7 M | 5.39 M | 26.8 M | 6.46 M | 5.39 M | 10.6 M | 24.5 M | 8.74 M | 10.6 M | 8.06 M | 28.6 M | 4.3 M | 8.06 M | 10.1 M | 42.5 M | 13.7 M | 10.1 M | 13.6 M | 42.8 M | 14.4 M | 13.6 M | 12.7 M | 40.4 M | 13.1 M | 12.7 M | 11.6 M | 44 M | 15.7 M | 11.6 M | 13.1 M | 37.2 M | 12.6 M | 13.1 M | 9.8 M | 30.2 M | 10.1 M | 9.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 51.8 M | -28.1 M | 18.7 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.01 | -0.12 % | $ 179 M | ||
|
Agilent Technologies
A
|
1.35 B | $ 118.05 | 0.44 % | $ 35.9 B | ||
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
-30.8 M | $ 20.96 | 1.26 % | $ 1.12 B | ||
|
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | ||
|
Co-Diagnostics
CODX
|
-50.2 M | $ 1.61 | 1.26 % | $ 2.14 M | ||
|
Castle Biosciences
CSTL
|
8.67 M | $ 24.81 | 0.85 % | $ 689 M | ||
|
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
25.2 M | $ 183.48 | -1.03 % | $ 9.09 B | ||
|
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | ||
|
Medpace Holdings
MEDP
|
535 M | $ 427.17 | -0.73 % | $ 12.3 B | ||
|
Myriad Genetics
MYGN
|
-387 M | $ 4.01 | -20.18 % | $ 371 M | ||
|
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | ||
|
NeoGenomics
NEO
|
-116 M | $ 8.89 | 0.28 % | $ 1.14 B | ||
|
National Research Corporation
NRC
|
22.6 M | $ 17.96 | -4.16 % | $ 402 M | ||
|
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.03 | 0.87 % | $ 454 M | ||
|
Natera
NTRA
|
-541 M | $ 217.47 | 5.17 % | $ 21.4 B | ||
|
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.16 | 2.68 % | $ 20 B | ||
|
Guardant Health
GH
|
-437 M | $ 92.19 | 2.98 % | $ 11.6 B | ||
|
Personalis
PSNL
|
-68.3 M | $ 6.01 | 8.09 % | $ 356 M | ||
|
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
1.1 B | $ 123.63 | 1.9 % | $ 10.2 B | ||
|
Illumina
ILMN
|
-833 M | $ 141.82 | 1.97 % | $ 22.5 B | ||
|
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.93 | 0.02 % | $ 2.69 B | ||
|
Senseonics Holdings
SENS
|
-68.3 M | $ 5.38 | 7.6 % | $ 224 M | ||
|
Interpace Biosciences
IDXG
|
4.08 M | $ 2.05 | 2.09 % | $ 9.07 M | ||
|
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | ||
|
Thermo Fisher Scientific
TMO
|
7.75 B | $ 472.27 | 1.18 % | $ 178 B | ||
|
Biomerica
BMRA
|
-5.14 M | $ 2.22 | 1.6 % | $ 5.1 M | ||
|
Lantheus Holdings
LNTH
|
311 M | $ 85.47 | -0.41 % | $ 5.77 B | ||
|
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.61 | 2.11 % | $ 61.9 M | ||
|
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 257.56 | 0.16 % | $ 21.4 B | ||
|
Twist Bioscience Corporation
TWST
|
-136 M | $ 59.55 | 5.03 % | $ 3.56 B | ||
|
Celcuity
CELC
|
-172 M | $ 139.94 | -1.24 % | $ 6.54 B | ||
|
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
-1.06 B | $ 9.16 | -1.13 % | $ 1.99 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 189.52 | -0.69 % | $ 21 B | ||
|
Waters Corporation
WAT
|
271 M | $ 348.15 | 1.58 % | $ 20.7 B |